Related references
Note: Only part of the references are listed.Paradoxical Aspects of Rapamycin Immunobiology in Transplantation
I. R. Ferrer et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors
Anne Dormond-Meuwly et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055
Gayle Marshall et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2011)
ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma
Didier Roulin et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2011)
Understanding the benefit of metformin use in cancer treatment
Ryan J. O. Dowling et al.
BMC MEDICINE (2011)
Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKBI-deficient mice
J. M. Garcia-Martinez et al.
BRITISH JOURNAL OF CANCER (2011)
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
Isaam Ben Sahra et al.
CANCER RESEARCH (2011)
Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
Beverly L. Falcon et al.
CANCER RESEARCH (2011)
Activation of mTORC2 by Association with the Ribosome
Vittoria Zinzalla et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma
Chintda Santiskulvong et al.
CLINICAL CANCER RESEARCH (2011)
Current and future directions in mammalian target of rapamycin inhibitors development
Angelica Fasolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate
Xiaoqing Gan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Targeting the JNK Signaling Pathway Potentiates the Antiproliferative Efficacy of Rapamycin in LS174T Colon Cancer Cells
Michael Benoit et al.
JOURNAL OF SURGICAL RESEARCH (2011)
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Eduardo Vilar et al.
MOLECULAR CANCER THERAPEUTICS (2011)
mTOR: from growth signal integration to cancer, diabetes and ageing
Roberto Zoncu et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mammalian target of rapamycin as a target in hematological malignancies
Kevin R. Kelly et al.
TARGETED ONCOLOGY (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell et al.
ONCOTARGET (2011)
Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of (Pre-)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial
R. Salgo et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
Carlos Garcia-Echeverria
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Ker Yu et al.
CANCER RESEARCH (2010)
Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2010)
Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
Yasemin Sancak et al.
CELL (2010)
Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Devalingam Mahalingam et al.
CLINICAL CANCER RESEARCH (2010)
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis et al.
CLINICAL CANCER RESEARCH (2010)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (Publication with Expression of Concern. See vol. 25, pg. 4194, 2019)
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sebastien Albert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
The mTOR Kinase Determines Effector versus Memory CD8+ T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin
Rajesh R. Rao et al.
IMMUNITY (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
Didier Roulin et al.
MOLECULAR CANCER (2010)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?
Issam Ben Sahra et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies
N. Chapuis et al.
LEUKEMIA (2010)
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Matthew R. Janes et al.
NATURE MEDICINE (2010)
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
Charles Swanton et al.
GENOME MEDICINE (2010)
The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity
M. D. Saeemann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
Thomas Decker et al.
ANNALS OF HEMATOLOGY (2009)
Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001
Philipp Baumann et al.
ANTI-CANCER DRUGS (2009)
Rapamycin inhibits mTORC1, but not completely
Carson C. Thoreen et al.
AUTOPHAGY (2009)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
K. Shoji et al.
BRITISH JOURNAL OF CANCER (2009)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Alexander E. Perl et al.
CLINICAL CANCER RESEARCH (2009)
Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Todd M. Morgan et al.
CURRENT CANCER DRUG TARGETS (2009)
Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer
Yan-Jie Zhang et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
Sherif S. Farag et al.
LEUKEMIA RESEARCH (2009)
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Erika L. Pearce et al.
NATURE (2009)
mTOR regulates memory CD8 T-cell differentiation
Koichi Araki et al.
NATURE (2009)
Molecular mechanisms of mTOR-mediated translational control
Xiaoju Max Ma et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
New Insights into mTOR Signaling: mTORC2 and Beyond
Dario R. Alessi et al.
SCIENCE SIGNALING (2009)
The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy
Anthony P. Monaco
TRANSPLANTATION (2009)
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Francesco P. Schena et al.
TRANSPLANTATION (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Nancy Lee et al.
BMC Pharmacology & Toxicology (2009)
Immunoregulatory functions of mTOR inhibition
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2009)
mTOR, cancer and transplantation
Edward K. Geissler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
Xuerong Wang et al.
CANCER BIOLOGY & THERAPY (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer
Aninda Basu et al.
CANCER RESEARCH (2008)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Arkaitz Carracedo et al.
CELL CYCLE (2008)
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma
Zheng Wang et al.
CLINICAL CANCER RESEARCH (2008)
Pilot study of rapamycin in patients with hormone-refractory prostate cancer
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2008)
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated Raptor phosphorylation
Audrey Carriere et al.
CURRENT BIOLOGY (2008)
mTOR inhibitors in the treatment of cancer
Angelica Fasolo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling
Maurice Phillip DeYoung et al.
GENES & DEVELOPMENT (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1
Yasemin Sancak et al.
SCIENCE (2008)
Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma
Patrizia Barozzi et al.
TRANSPLANTATION (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia
C. Sillaber et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome- a single-centre experience and review of the literature
Stefan M. Weiner et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and mnk-mediated eukaryotic translation initiation factor 4E phosphorylation
Xuerong Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells
Olivier Dormond et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma
Hashem Younes et al.
CLINICAL CANCER RESEARCH (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells
Takayuki Ikezoe et al.
LEUKEMIA RESEARCH (2007)
The regulation of AMPK β1, TSC2, and PTEN expression by p53:: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways
Zhaohui Feng et al.
CANCER RESEARCH (2007)
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Yasemin Sancak et al.
MOLECULAR CELL (2007)
Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation
Yael Mamane et al.
PLOS ONE (2007)
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα but not S6K1
David A. Guertin et al.
DEVELOPMENTAL CELL (2006)
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts
Diana C. Birie et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Expression of mTOR signaling pathway markers in prostate cancer progression
Celeste L. Kremer et al.
PROSTATE (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
Increased cancer-related mortality for patients with type 2 diabetes who use sulforrylureas or insulin
SL Bowker et al.
DIABETES CARE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance
Kian-Huat Lim et al.
CELL (2006)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
Li Ma et al.
CELL (2006)
Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance
KH Lim et al.
CANCER CELL (2005)
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
RD Rao et al.
NEOPLASIA (2005)
Metformin and reduced risk of cancer in diabetic patients
JMM Evans et al.
BMJ-BRITISH MEDICAL JOURNAL (2005)
Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-κB activation in endothelial cells
M Minhajuddin et al.
JOURNAL OF IMMUNOLOGY (2005)
Phosphorylation and functional inactivation of TSC2 by Erk: Implications for tuberous sclerosis and cancer pathogenesis
L Ma et al.
CELL (2005)
Sirolimus for Kaposi's sarcoma in renal-transplant recipients
G Stallone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Antileukemic activity of rapamycin in acute myeloid leukemia
C Récher et al.
BLOOD (2005)
Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients
KS Ozaki et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma
JM Campistol et al.
TRANSPLANTATION (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome
MN Corradetti et al.
GENES & DEVELOPMENT (2004)
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
A Boulay et al.
CANCER RESEARCH (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
HB Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo
H Hackstein et al.
BLOOD (2003)
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin
MB Dilling et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
MS Neshat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Rapamycin in transplantation: A review of the evidence
RN Saunders et al.
KIDNEY INTERNATIONAL (2001)
Share Paper
